TrialJBMR plus2026

Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis.

Richard Eastell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.